ReviewCurrent cardiology reports2000
Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.
Review in Current cardiology reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Guideline
- Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2020Pooled it
- ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.Critical care (London, England) · 2024Trial
- Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.Journal of veterinary internal medicineTrial
- Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?Current hypertension reports · 2022Review
- The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2022Article
- Treatment of proteinuria in dogs with telmisartan: A retrospective study.Journal of veterinary internal medicine · 2021Article
- Chymase Dependent Pathway of Angiotensin II Generation and Rapeseed Derived Peptides for Antihypertensive Treatment of Spontaneously Hypertensive Rats.Frontiers in pharmacology · 2021Article
- Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014).Korean circulation journal · 2020Article
- Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue.The Journal of surgical research · 2020Article
- Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2019Article
- Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue.Therapeutic advances in cardiovascular disease · 2015Article
- Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.British journal of pharmacology · 2010Review
- Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- Should we employ combination ACEI and ARB therapy in primary hypertension?Current hypertension reports · 2006Article
- Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice.Journal of clinical hypertension (Greenwich, Conn.)Review
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice.Journal of clinical hypertension (Greenwich, Conn.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The level of inhibition of the angiotensin-converting enzyme (ACE) provided by standard doses of ACE inhibitors may only be partial during long-term treatment in patients with severe chronic heart failure (CHF). Partial ACE inhibition with time is often referred to as escape from ACE inhibition and labeled ACE escape. Several lines of evidence suggest that ACE escape occurs in patients with severe CHF. Plasma levels of angiotensin II rise above initial values during long-term ACE inhibition, and the effects of ACE inhibitors on cardiac remodeling and lowering of sympathetic nervous system activity attenuate after 1 year of treatment. Moreover, angiotensin II type I receptor blockade (ARB) produces clinical and hemodynamic benefits in patients with CHF who are already receiving ACE inhibitors. The therapeutic implications of ACE escape include evaluation of higher- than-standard doses of ACE inhibitors and routine addition of ARB to ACE inhibition in patients with severe CHF. Data are reviewed to demonstrate that ACE escape reflects inadequate ACE dosage rather than a decrease in ACE inhibition occurring with time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.